Soluble biomolecular glass and use thereof

Soluble biomolecular glasses were prepared by heating and pressurizing in an aqueous solution, solving the high-temperature decomposition and oxidation problems of the traditional melt-quenching method. This resulted in soluble biomolecular glasses with high transparency and good bioactivity, suitable for medical, health monitoring and electronic device fields.

WO2024229600A1PCT designated stage expired Publication Date: 2024-11-14INSTITUTE OF PROCESS ENGINEERING CHINESE ACADEMY OF SCIENCES
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/092307
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-05
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

In existing technologies, the traditional melt-quench method for preparing amino acid/peptide glasses suffers from high-temperature decomposition, oxidation, and complexity, resulting in reduced glass transparency and bioactivity, and is also not environmentally friendly.

Method used

Soluble biomolecular glasses are prepared by heating and/or pressurizing an aqueous solution and then evaporating the solvent. Natural amino acids or peptides and their derivatives, regulators, and aqueous solvents are used to form amorphous soluble biomolecular glasses.

Benefits of technology

The prepared soluble biomolecular glass has excellent biocompatibility, high light transmittance, good mechanical strength and flexible processability. It can be degraded in organisms or ecological environments, and the degradation products are green and environmentally friendly.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023092307_14112024_PF_FP_ABST
    Figure CN2023092307_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a biomolecular glass and a use thereof. The biomolecular glass is obtained from a biomolecular raw material solution by means of a volatile solvent, and the biomolecular raw material solution comprises a biomolecular raw material, a regulator, and a solvent; the biomolecular raw material comprises a natural amino acid or a peptide or an amino acid derivative or a peptide derivative, or a mixture of two or more thereof. The soluble biomolecular glass of the present invention has excellent biocompatibility, high light transmittance, good mechanical strength, flexible processability and biodegradability, can be processed into implantable or non-implantable medical materials and / or devices, filling and scaffold materials, electronic sensing materials and / or devices, transient electronic materials and / or devices, etc., and can be degraded by organisms or in nature, and degradation products are pollution-free.
Need to check novelty before this filing date? Find Prior Art

Description

Soluble biomolecule glass and its application Technical Field

[0001] The present invention relates to a soluble biomolecule glass, a preparation method, and its application, belonging to the technical field of materials and their preparation methods. The present invention discloses a type of soluble biomolecule glass based on amino acids and peptides, as well as a method for preparing the glass by solvent evaporation from a biomolecule solution. Such soluble biomolecule glass can be processed into implantable or non-implantable medical materials and / or devices, filling and scaffolding materials, electronic sensor materials and / or devices, and transient electronic materials and / or devices, with applications in healthcare, health monitoring, security encryption, information transmission, and storage. Background Art

[0002] Glass is an amorphous solid characterized by transparency, high hardness, and corrosion resistance. It enjoys a wide range of applications, including: 1) as a key building material, it is widely used in building facades, roofs, partitions, doors and windows, stair railings, skylights, and more; 2) due to its excellent electrical properties, it is widely used in electronic devices such as display screens, touch screens, and fiber optic transmission chips. Glass possesses unique physical, chemical, and mechanical properties, and with the continuous advancement and innovation of science and technology, its applications continue to expand.

[0003] Glass is chemically very stable, making it difficult for natural degradation to occur. Glass products can persist in the natural environment for extended periods, placing a significant ecological burden. Biomolecules, particularly amino acids and peptides, possess excellent biocompatibility and biodegradability. Researchers have already utilized these biomolecules to create biodegradable glass.

[0004] Currently, biomolecular glasses prepared using the traditional melt-quenching method have been disclosed. For example, a biodegradable glass based on amino acids, peptides, and derivatives has been disclosed (CN 113754556 B); cyclic peptide glass and pharmaceutical composition glass containing cyclic peptides have also been disclosed (CN114014908A). However, the traditional melt-quenching method for preparing amino acid / peptide glasses has significant limitations. First, amino acid / peptide molecules have high melting points and are prone to thermal decomposition before high-temperature melting. Second, the high-temperature melting and low-temperature quenching processes are complex and not environmentally friendly. Third, amino acid / peptide molecules are prone to oxidation under high-temperature conditions, affecting the light transmittance and transparency of the glass. Furthermore, increasing the temperature causes changes in the structure or conformation of amino acid / peptide molecules, which also severely reduces the biological activity of amino acids / peptides. Therefore, the melt-quenching method for preparing biomolecular glasses is limited.

[0005] Currently, no methods for preparing amino acid / peptide glasses other than the "melt-quench" method have been disclosed. Surprisingly, the present invention discovered that amino acid / peptide molecules can form glasses in aqueous solutions by adding a modifier and subsequently evaporating the solvent. These amino acid / peptide biomolecular glasses are water-soluble and biodegradable by organisms or nature, and the degradation products are completely green and environmentally friendly. Compared to traditional melt-quench methods, this method is simpler, gentler, more controllable, and more environmentally friendly.

[0006] The present invention is based on this discovery. The soluble biomolecular glass and biomolecular glass materials and / or devices developed based on this invention are expected to be used in the preparation of implantable or non-implantable medical materials and / or devices, filling and scaffold materials, electronic sensor materials and / or devices, and transient electronic materials and / or devices, with applications in healthcare, health monitoring, security encryption, information transmission and storage, and other fields.

[0007] Summary of the Invention

[0008] The primary objective of the present invention is to provide soluble biomolecule glass and a method for preparing the same. The primary raw materials are natural amino acids, peptides, amino acid derivatives, peptide derivatives, or mixtures of these two or more, a modifier, and an aqueous solvent. Different from the previously disclosed "melt-quench" method for preparing amino acid / peptide glass (CN 113754556 B, CN114014908A), the present invention discloses a method for preparing glass by heating and / or pressurizing an aqueous biomolecule solution to evaporate the solvent.

[0009] The soluble biomolecular glass of the present invention exhibits excellent biocompatibility, high light transmittance, good mechanical strength, and flexible processability. The soluble glass produced by this method can be processed into implantable or non-implantable medical materials and / or devices, filling and scaffold materials, electronic sensor materials and / or devices, and transient electronic materials and / or devices. It is biodegradable or biodegradable, and the degradation products are completely green and environmentally friendly.

[0010] The soluble biomolecular glass and preparation method thereof of the present invention can be applied to fields such as medical care, health monitoring, security encryption, information transmission and storage.

[0011] In a first aspect, a biomolecular glass is provided, characterized in that the biomolecular glass is obtained from a solution of a biomolecular raw material by volatilizing a solvent, wherein the solution of the biomolecular raw material comprises a biomolecular raw material, a regulator and a solvent; and the biomolecular raw material comprises a natural amino acid or a peptide or an amino acid derivative or a peptide derivative or a mixture of the above two or more.

[0012] In a second aspect, the soluble biomolecule glass is characterized in that the biomolecule raw material is a natural amino acid or a peptide or an amino acid derivative or a peptide derivative or a mixture of two or more of the above:

[0013] Specifically,

[0014] A natural amino acid molecule of formula (1), or an amino acid derivative, or a pharmaceutically acceptable salt thereof, any one of the foregoing, or a mixture of two or more thereof;

[0015] The amino acids include glycine, alanine, valine, leucine, isoleucine, methionine (methionine), proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine ​​and pyrrolysine;

[0016] or, a peptide molecule formed by peptide bond condensation of formula (1), or a peptide derivative, or a pharmaceutically acceptable salt thereof, any one of the foregoing or a mixture of two or more thereof;

[0017] The peptide is a molecule formed by condensing n of the above amino acids through peptide bonds, wherein n ≥ 2, preferably, 2 ≤ n ≤ 10;

[0018] The protective groups of the derivatives of the above-mentioned amino acids or peptides include but are not limited to: Trt, Boc, Fmoc, Cbz / Z, Allyl, C2-C18 acyl, benzoyl, naphthoyl, OFm, Otbu, OBzl, OAll, OMe, and OEt.

[0019] In a third aspect, the soluble biomolecule glass is characterized in that the modulator is selected from nucleotides, nucleotide polymers, RNA, DNA and / or other modulators, or a mixture of two or more of the above;

[0020] For example,

[0021] Nucleotides include, but are not limited to, adenosine-5′-monophosphate (AMP), nicotinamide mononucleotide (NMN), guanosine-5′-monophosphate (GMP), uridine-5′-monophosphate (UMP), cytidine-5′-monophosphate (CMP), and adenosine-3′-monophosphate (3-AMP);

[0022] Other modulators include, but are not limited to, D / L-tartaric acid, hydrochloric acid, sulfuric acid, phosphoric acid, lactic acid, polylactic acid, hyaluronic acid, alginic acid, lactobionic acid, citric acid, tartaric acid, oxalic acid, D / L-malic acid, maleic acid, hibiscus acid, acamprosate, quinic acid, adipic acid, fumaric acid, caproic acid, heptanoic acid, caprylic acid, valeric acid, butyric acid, propionic acid, and glacial acetic acid;

[0023] Preferably, it is hydrochloric acid, nucleotide, citric acid, glacial acetic acid, or malic acid.

[0024] In a fourth aspect, the above-mentioned soluble biomolecule glass is characterized in that the solvent is water or a salt solution thereof.

[0025] In a fifth aspect, a method for preparing soluble biomolecule glass comprises the following steps:

[0026] (1) Weigh the biomolecule raw materials, mix and grind them evenly;

[0027] (2) dissolving the raw material powder of step (1) in a solvent to obtain a biomolecule solution;

[0028] (3) adding a regulator to the biomolecule solution of step (2) and adjusting the final pH value of the solution by controlling the amount of the regulator; if the regulator is a mixed solution, it needs to be pre-mixed;

[0029] (4) placing the aqueous solution of step (3) in a container, and volatilizing the solvent by adjusting the solution temperature, and / or applying pressure, and / or vacuum, to prepare soluble biomolecule glass.

[0030] In a sixth aspect, the soluble biomolecule glass and preparation method are characterized in that the pH of the biomolecule solution after adding the regulator is 1 to 8, preferably, 4 to 7.

[0031] In a seventh aspect, the above-mentioned soluble biomolecule glass and preparation method are characterized in that the solvent can be evaporated by air flow, spray, fluidized bed, rotary flash evaporation, infrared, microwave, freezing / vacuum freezing.

[0032] In an eighth aspect, the above-mentioned soluble biomolecule glass and preparation method are characterized in that the solvent volatilization time is 20 minutes to 7 hours, preferably, 40 minutes to 4 hours.

[0033] In the ninth aspect, the above-mentioned soluble biomolecule glass and preparation method are characterized in that the mass percentage of the biomolecule raw material in the glass is 50-99.5wt%, preferably 85-99wt%; the mass percentage of the regulator in the glass is 0-50wt%, preferably 0-15wt%, and more preferably greater than 0wt%; the mass percentage of the solvent in the glass is 0.05-5wt%, preferably 0.1-2wt%.

[0034] In a tenth aspect, the above-mentioned soluble biomolecule glass and preparation method are characterized in that there is a strong hydrogen bond interaction between the biomolecules and the regulator and / or solvent, and the biomolecule glass is rich in hydrogen bond networks.

[0035] Eleventhly, the soluble biomolecule glass is characterized in that it is an amorphous body in a glassy state, i.e., an amorphous solid, exhibiting isotropy, no fixed melting point, and reversibility.

[0036] In a twelfth aspect, the soluble biomolecule glass is characterized by having a glass transition temperature (Tg), which is adjustable within the range of 0 to 200°C.

[0037] Preferably, the Tg of the soluble biomolecule glass is 20°C <Tg<200℃。

[0038] More preferably, the Tg range of the soluble biomolecule glass is 20°C <Tg<160℃。

[0039] In the thirteenth aspect, the above-mentioned soluble biomolecule glass is characterized by having good glass forming ability (GFA), that is, the Tg (glass transition temperature) / Tm (melting point temperature) ratio is distributed between 0.55 and 0.75, preferably, between 0.66 and 0.75.

[0040] In a fourteenth aspect, the soluble biomolecule glass is characterized in that the performance indicators of the soluble biomolecule glass are as follows:

[0041] At a thickness of 1mm and a wavelength of 500nm,

[0042] The light transmittance is 40-99%, preferably 80-99%;

[0043] The hardness is greater than 20 MPa, preferably, the hardness is greater than 50 MPa.

[0044] In the fifteenth aspect, the above-mentioned soluble biomolecule glass is characterized in that it can be processed into implantable or non-implantable medical materials and / or devices, filling and support materials, electronic sensor materials and / or devices, transient electronic materials and / or devices, and the processing method can be spin coating, casting, electrospinning, and 3D printing.

[0045] In the sixteenth aspect, the above-mentioned soluble biomolecular glass and biomolecular glass materials and / or devices are characterized in that they can be degraded by organisms or ecological environments; preferably, they can be degraded at room temperature and / or human body temperature, in a composting environment; and more preferably, they can achieve transient dissolution in aqueous solutions, blood, tissue fluids, and body fluid environments.

[0046] In the seventeenth aspect, the above-mentioned soluble biomolecular glass and biomolecular glass materials and / or devices are characterized in that the dissolution time can be controllably adjusted according to the glass raw materials, size, and structure, ranging from 0.5 minutes to 3.5 months; the dissolution rate can be adjusted and / or controlled according to the controllable adjustment of the glass raw materials, size, and structure.

[0047] In an eighteenth aspect, the above-mentioned soluble biomolecular glass and biomolecular glass materials and / or devices are characterized in that they can achieve complete degradation and / or transient dissolution.

[0048] In a nineteenth aspect, the soluble biomolecular glass and biomolecular glass materials and / or devices are characterized in that they can be applied in fields such as healthcare, health monitoring, security encryption, information transmission and storage:

[0049] Preferably, it can be used for the processing and preparation of soluble glass microneedles, which can be used to pierce the skin and / or mucous membranes, blood-eye barrier, blood-brain barrier, etc. for pharmaceutical purposes;

[0050] and / or for use in soluble supercapacitors, chips, glass electrodes, transient circuits / memory, etc., for pharmaceutical or sensing or electronic applications;

[0051] And / or used in soluble stents, preferably bone stents, and / or heart stents, and / or vascular stents, etc., for pharmaceutical or medical purposes. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] FIG1 is a photograph of the arginine glass prepared in Example 1.

[0053] FIG2 is a mass spectrum of the arginine glass prepared in Example 1, which shows that the amino acid molecular structure after preparation is stable.

[0054] FIG3 is a degradation curve of the arginine glass prepared in Example 1 in industrial wastewater and industrial soil, confirming its degradability.

[0055] FIG4 is a physical picture of the phenylalanine solid glass prepared in Example 2 at room temperature, which can be processed into glass blocks or glass fibers as needed, demonstrating its strong machinability.

[0056] FIG5 is a microscope image of the phenylalanine glass prepared in Example 2 and phenylalanine crystals in bright field and polarized field, demonstrating that the formed amino acid glass has an amorphous structure.

[0057] FIG6 is an infrared spectrum of the phenylalanine glass and the phenylalanine crystal prepared in Example 2. The infrared spectrum peak of the glass is significantly broadened, indicating that the molecules in the phenylalanine glass are disordered.

[0058] FIG7 shows the DSC spectrum and TG spectrum of the histidine solid glass prepared in Example 3.

[0059] FIG8 is an XRD pattern of tyrosine crystal powder and glass in Example 4.

[0060] FIG. 9 shows the transmittance of the aspartic acid solid glass in Example 5.

[0061] FIG10 is a sustained-release curve of the exenatide glass prepared in Example 5.

[0062] FIG11 shows the release curves of aspartic acid glass and crystal prepared in Example 5.

[0063] FIG12 is a photograph of the glass of thymopentin in Example 8.

[0064] FIG13 is a photograph of the glass formed by the thymopentin in the mold in Example 9.

[0065] FIG14 is a photograph of the glass of Exenatide in Example 10.

[0066] FIG15 is a curve showing the regulation of blood glucose by the aspartic acid glass prepared in Example 5 on spontaneous type II diabetic mice.

[0067] FIG16 is an XRD pattern of the Boc-Val glass and crystal powder in Example 6.

[0068] FIG17 is a polarizing microscope image of a solid glass of the composition of N-acetyl-L-threonine and L-arginine in Example 7.

[0069] FIG18 is the in vivo pharmacodynamic evaluation of the thymopentin solid-state glass in rats in Example 8.

[0070] FIG. 19 shows the neurological function scores of Tuftsin in experimental autoimmune encephalomyelitis (EAE) mice in Example 9.

[0071] Figure 20 is a physical picture of the microneedles prepared in Example 29.

[0072] FIG21 is a photograph of the optical waveguide of the phenylalanine glass optical fiber prepared in Example 31 that conducts laser light.

[0073] FIG22 shows the disappearance process of the simulated circuit in Example 32 when it comes into contact with water.

[0074] FIG23 shows the disappearance process of the interdigitated electrodes in Example 33 when exposed to water. DETAILED DESCRIPTION

[0075] The technical solutions of the present invention are described in detail below through examples, but the protection content of the present invention is not limited thereto.

[0076] Example 1

[0077] A method for preparing arginine-based bioglass comprises the following steps:

[0078] Prepare 250 ml of 0.01 M citric acid aqueous solution for later use;

[0079] Weigh 500 mg of L-arginine powder and grind it evenly in a mortar;

[0080] The arginine powder in step (2) was placed in a 500 ml round-bottom flask, and 20 ml of ultrapure water was added until the arginine powder was completely dissolved to obtain an arginine solution;

[0081] Add 20 ml of the citric acid aqueous solution in step (1) to the arginine solution in step (3) until the pH of the arginine solution is 6.0;

[0082] The arginine solution in step (4) was heated at 10 K min -1 The round-bottom flask was heated to 373 K at a heating rate of , and the solvent was evaporated at this temperature by constant temperature treatment for 2 h; thus, arginine (Arg)-based glass was obtained.

[0083] Figure 1 is a physical image of the arginine glass prepared in Example 1. As shown in Figure 1, it can be seen that it has good optical properties. The transmittance at 500nm was further measured by ultraviolet spectrometry (sample thickness 1mm), and the results are listed in Table 1. The mass spectrum of the prepared arginine glass is shown in Figure 2. The results show that the amino acid molecular structure after preparation is stable and no oxidation or decomposition occurs. The glass transition temperature Tg of the prepared glass is 337K, the melting point Tm is 495K, and the Tg / Tm ratio is 0.68, indicating that it has good glass-forming ability. Figure 3 shows the degradation curve of the arginine glass prepared in Example 1 (mass 32.2mg) in industrial soil and industrial wastewater, confirming that the arginine glass can be degraded in the environment.

[0084] Example 2

[0085] A method for preparing phenylalanine-based bioglass comprises the following steps:

[0086] Prepare 250 ml of 0.2 M citric acid aqueous solution for later use;

[0087] Weigh 1g of L-phenylalanine powder and grind it evenly in a mortar;

[0088] The phenylalanine powder in step (2) was placed in a 500 ml round-bottom flask, and 20 ml of ultrapure water was added until the phenylalanine powder was completely dissolved to obtain a phenylalanine solution;

[0089] Add 20 ml of the citric acid solution in step (1) to the phenylalanine solution in step (3) until the pH of the phenylalanine solution reaches 5.0;

[0090] The phenylalanine solution in step (4) was subjected to a constant temperature heating treatment at 40K min -1Heat the round-bottom flask to 363 K at a heating rate of 1000 rpm and keep it at 363 K for 2.5 h.

[0091] After the solution in the round-bottom flask in step (5) shows a viscous flow, continue to maintain constant temperature for 30 minutes, then cool the equipment to 40K min -1 The cooling rate was reduced to 273 K and maintained for 30 min to obtain phenylalanine (Phe) biomolecular glass.

[0092] The actual picture of the prepared phenylalanine solid glass at room temperature is shown in Figure 4. It can be processed into glass blocks or glass fibers as needed, proving that it has strong processability. Figure 5 is a microscope picture of the phenylalanine glass and phenylalanine crystals prepared in Example 2 in bright field and polarized field, proving that the formed amino acid glass is an amorphous structure. Figure 6 is an infrared spectrum of the phenylalanine glass and phenylalanine crystals prepared in Example 2. The infrared spectrum peak of the glass is significantly broadened, indicating that the molecules in the phenylalanine glass are disordered. Further measurements of the prepared glass showed that the glass transition temperature Tg = 400K, the melting point Tm = 556K, and the Tg / Tm ratio was 0.72, indicating that it has good glass-forming ability.

[0093] Example 3

[0094] A method for preparing histidine-based bioglass comprises the following steps:

[0095] Prepare 250 ml of 0.1 M hydrochloric acid solution for later use;

[0096] Weigh 1g of L-histidine powder and grind it evenly in a mortar;

[0097] The histidine powder in step (2) was placed in a 500 ml round-bottom flask, and 20 ml of ultrapure water and 1 ml of ethanol were added respectively until the histidine powder was completely dissolved to obtain a histidine solution;

[0098] Add 20 ml of the hydrochloric acid aqueous solution in step (1) to the histidine solution in step (3) until the pH of the histidine solution is 5.0;

[0099] The histidine solution in step (4) was heated at a constant temperature of 50K min -1 The round-bottom flask was heated to 383 K at a heating rate of 50 K min and kept at 383 K for 1.5 h. The equipment was then cooled at a heating rate of 50 K min -1 The temperature was cooled to 293 K at a rate of 1000 K and maintained at that temperature for 30 min to obtain histidine (His) solid glass.

[0100] FIG7 shows the DSC spectrum and TGA spectrum of the histidine solid glass prepared in Example 3. The glass transition temperature Tg is 375 K, the melting point Tm is 559 K, and the Tg / Tm ratio is 0.67, indicating that the solid histidine glass has good glass-forming ability.

[0101] Example 4

[0102] A method for preparing tyrosine-based bioglass comprises the following steps:

[0103] Prepare 100 ml of 0.5 M acetic acid aqueous solution for later use;

[0104] Weigh 2g of L-tyrosine powder and grind it evenly in a mortar;

[0105] The tyrosine powder in step (2) was placed in a 500 ml round-bottom flask, and 30 ml of ultrapure water was added until the tyrosine powder was completely dissolved to obtain a tyrosine solution;

[0106] Add 20 ml of the acetic acid aqueous solution in step (1) to the tyrosine solution in step (3) until the pH of the tyrosine solution is 5.5;

[0107] The tyrosine solution in step (4) was subjected to a constant temperature heating treatment at 50K min -1 Heat the round-bottom flask to 383 K at a heating rate of 1000 K and keep it at 383 K for 10 min.

[0108] The equipment in step (5) was cooled to 50K min -1 The cooling rate dropped to 293K;

[0109] The tyrosine solution in step (6) is subjected to room temperature volatilization of the solvent and maintained for 20 days to obtain tyrosine bioglass.

[0110] Figure 8 shows the XRD patterns of the tyrosine crystalline powder and glass in Example 4, demonstrating that the tyrosine glass is amorphous. Further measurements of the prepared glass revealed a glass transition temperature (Tg) of 344 K, a melting point (Tm) of 617 K, and a Tg / Tm ratio of 0.67, indicating good glass-forming ability.

[0111] Example 5

[0112] A method for preparing aspartic acid-based bioglass comprises the following steps:

[0113] Prepare 500 ml of 0.3 M citric acid aqueous solution for later use;

[0114] Weigh 500 mg of L-aspartic acid powder in a mortar and grind evenly;

[0115] The aspartic acid powder in step (2) was placed in a 500 ml round-bottom flask, and 30 ml of ultrapure water was added until the aspartic acid powder was completely dissolved to obtain an aspartic acid solution;

[0116] Add 20 ml of the citric acid aqueous solution in step (1) to the aspartic acid solution in step (3) until the pH of the aspartic acid solution is 5.0;

[0117] The aspartic acid solution in step (4) was subjected to a constant temperature heating treatment at 30K min -1 The round-bottom flask was heated to 383 K at a heating rate of 50 K min -1 The cooling rate was reduced to 293K and maintained for 30min to obtain aspartic acid (Asp) bioglass.

[0118] Figure 9 shows the transmittance of the aspartic acid solid glass in Example 5, which is close to 99%. Further measurements show that the prepared glass has a glass transition temperature (Tg) of 377K, a melting point (Tm) of 503K, and a Tg / Tm ratio of 0.75, indicating good glass-forming ability.

[0119] Example 6

[0120] A method for preparing valine-based bioglass comprises the following steps:

[0121] Prepare 500 ml of 0.01 M malic acid aqueous solution for later use;

[0122] Weigh 500 mg of N-tert-butyloxycarbonyl-L-valine (Boc-Val) powder in a mortar and grind evenly;

[0123] Place the Boc-Val powder in step (2) in a 500 ml round-bottom flask, add 30 ml of ultrapure water and 3 ml of propylene glycol, respectively, and wait until the Boc-Val powder is completely dissolved to obtain a Boc-Val solution;

[0124] Add 20 ml of the malic acid aqueous solution in step (1) to the Boc-Val solution in step (3) until the pH of the Boc-Val solution is 5.5;

[0125] The Boc-Val solution in step (4) was heated at a constant temperature of 10 K min -1 The temperature was heated to 323 K at a heating rate of 1000 K and kept at 323 K for 5 h;

[0126] When the solution in the round-bottom flask in step (5) becomes viscous, the N-tert-butyloxycarbonyl-L-valine (Boc-Val)-based glass is obtained.

[0127] Figure 10 shows the XRD patterns of the Boc-Val glass and its crystalline powder in Example 6, demonstrating the amorphous nature of the Boc-Val glass. Further measurements of the prepared glass revealed a glass transition temperature (Tg) of 406 K, a melting point (Tm) of 588 K, and a Tg / Tm ratio of 0.69, indicating good glass-forming ability.

[0128] Example 7

[0129] A method for preparing glass based on a threonine and arginine composition comprises the following steps:

[0130] Prepare 50 ml of 0.01 M citric acid aqueous solution for later use;

[0131] Weigh 1g of N-acetyl-L-threonine powder and 1g of L-arginine powder in a mortar and grind them evenly;

[0132] The mixed powder of N-acetyl-L-threonine and arginine in step (2) was placed in a 500 ml round-bottom flask, and then 40 ml of ultrapure water was added until the amino acid mixed powder was completely dissolved to obtain an amino acid solution;

[0133] Add 40 ml of the citric acid aqueous solution in step (1) to the amino acid solution in step (3) until the pH of the amino acid solution is 5.0;

[0134] The amino acid solution in step (4) was heated at a constant temperature of 50 K min -1 Heat the round-bottom flask to 383 K at a heating rate of 1.5 h and keep it at 383 K for 1.5 h.

[0135] After the solution in the round-bottom flask in step (5) becomes viscous, the temperature is maintained for 20 min, and then the equipment is cooled to 50 K min. -1 The temperature was lowered to 293 K at a cooling rate of 0.1°C and maintained for 30 min to obtain a solid glass of N-acetyl-L-threonine and L-arginine composition.

[0136] FIG11 is a polarizing microscope image of the solid glass of the N-acetyl-L-threonine and L-arginine composition in Example 7 (bright field on the left, polarized field on the right), demonstrating that the mixed solid glass is amorphous.

[0137] Example 8

[0138] A method for preparing solid-state glass based on thymopentin comprises the following steps:

[0139] Prepare 50 ml of 0.01 M citric acid aqueous solution for later use;

[0140] Weigh 10 mg of thymopentin powder and grind it into a mortar and mix it evenly;

[0141] The thymopentin powder in step (2) was placed in a 250 ml round-bottom flask, and then 10 ml of ultrapure water was added until the thymopentin powder was completely dissolved to obtain a thymopentin solution;

[0142] Add 10 ml of the citric acid aqueous solution in step (1) to the amino acid solution in step (3) until the pH of the thymopentin solution is 6.0;

[0143] The amino acid solution in step (4) was heated at a constant temperature of 50 K min -1 The round-bottom flask was heated to 383 K at a heating rate of 50 K min and kept at 383 K for 1.5 h. After the solution in the round-bottom flask in step (5) became viscous, the temperature was kept constant for 20 min, and then the equipment was cooled at a rate of 50 K min -1 The cooling rate was reduced to 293 K and maintained for 30 min to obtain a solid glass based on thymopentin.

[0144] FIG12 is a photo of the glass of thymopentin in Example 8, which is transparent.

[0145] Example 9

[0146] A method for preparing tuftsin-based glass comprises the following steps:

[0147] Prepare 50 ml of 0.01 M malic acid aqueous solution for later use;

[0148] Weigh 10 mg of tuftsin powder and grind it into a mortar and mix evenly;

[0149] The tuftsin powder prepared in step (2) was placed in a 250 ml round-bottom flask, and 10 ml of ultrapure water was added until the tuftsin powder was completely dissolved to obtain a tuftsin solution;

[0150] Add 10 ml of the malic acid aqueous solution in step (1) to the amino acid solution in step (3) until the pH of the tuftsin solution is 6.0;

[0151] The amino acid solution in step (4) was heated at a constant temperature of 10K min -1 The round-bottom flask is heated to 363 K at a heating rate of 100 K and maintained at 363 K for 2 h. After the solution in the round-bottom flask in step (5) becomes a viscous fluid, the temperature is maintained for 30 min, and then the equipment is cooled at a rate of 40 K min -1 The cooling rate was reduced to 293 K and maintained for 30 min to obtain a solid glass based on tuftsin.

[0152] FIG13 shows the glass of thymopentin formed in the mold in Example 9, which confirms the processability of the peptide glass.

[0153] Implementation 10

[0154] A method for preparing exenatide-based glass comprises the following steps:

[0155] Prepare 50 ml of 0.01 M malic acid aqueous solution for later use;

[0156] Weigh 10 mg of exenatide powder and grind it into a mortar and mix evenly;

[0157] The exenatide powder in step (2) was placed in a 250 ml round-bottom flask, and then 10 ml of ultrapure water was added until the exenatide powder was completely dissolved to obtain an exenatide solution;

[0158] Add 10 ml of the malic acid aqueous solution in step (1) to the amino acid solution in step (3) until the pH of the exenatide solution is 6.0;

[0159] The amino acid solution in step (4) was heated at a constant temperature of 10K min -1 The round-bottom flask is heated to 363 K at a heating rate of 100 K and maintained at 363 K for 2 h. After the solution in the round-bottom flask in step (5) becomes a viscous fluid, the temperature is maintained for 30 min, and then the equipment is cooled at a rate of 40 K min -1 The cooling rate was reduced to 293 K and maintained for 30 min to obtain a solid glass based on exenatide.

[0160] FIG14 is a photo of the glass of Exenatide in Example 10, which is transparent.

[0161] Examples 11-20

[0162] The exenatide in Example 10 was replaced with equal masses of Arg-Arg, Arg-Gly-Asp, Thr-Lys-Pro-Arg, glutathione, vancomycin hydrochloride, Ac-Ala, Ac-Ala-Gln, Cbz-Phe-Phe, Cbz-Phe-Phe-Gly, and Tyr-Ser-Pro-Thr-Ser-Pro-Ser to prepare the corresponding biomolecular glass, and the transmittance and hardness of the prepared glass were measured.

[0163] Method for measuring transmittance: The glass prepared in each example was processed into a circular glass with a diameter of 1 cm and a thickness of 1 mm, and its transmittance at 500 nm was measured using an ultraviolet spectrophotometer (model: Shimadzu UV-1900i).

[0164] Hardness measurement method: The hardness of biomolecular glass was measured by G200 nanoindenter (Agilent). Measurement method: A triangular pyramid diamond indenter was used at a constant strain rate (0.05s -1 ) was pressed into the glass material and the load force was plotted against the displacement to obtain the hardness data for each biomolecular glass. The results are shown in the following table:

[0165] Implementing 21 glass light stability tests

[0166] Specifically, the glass prepared in each embodiment was processed into a glass disc with a diameter of 1 cm and a thickness of 1 mm, and placed in a light environment. The lighting conditions were: xenon lamp (Philips), light intensity: 6000xls; the appearance of the glass disc was observed after 7 days, 15 days, and 30 days, and its transmittance at 500 nm was measured. The results are listed in Table 2.

[0167] The above results confirm that the prepared glass has good light stability.

[0168] Conduct high temperature stability test on 22 glass

[0169] Specifically, the glass prepared in each embodiment was processed into a circular glass with a diameter of 1 cm and a thickness of 1 mm, and placed in a high temperature and high humidity environment (ambient temperature 50°C, 96% relative humidity); observations were made at 0 days, 15 days, and 30 days, and the results are listed in Table 3.

[0170] The above results confirm that the prepared glass has good high temperature stability.

[0171] Sustained release curve of the exenatide glass prepared in Example 23

[0172] Specifically, the exenatide glass was prepared with an initial mass of 30 ± 1 mg, a sustained-release solvent of 10 mL phosphate buffer (0.01 M, pH = 6.8), and a stirring rate of 100 r min. -1 At different time points, the upper layer solution was taken and the dissolved exenatide was detected by high performance liquid chromatography. High performance liquid chromatography (HPLC) conditions: Liquid elution conditions: mobile phase A-water (0.1% TFA), mobile phase B-acetonitrile (0.1% TFA); elution gradient: mobile phase B 20%-60%, 0-16min; flow rate 1mLmin -1 , detection wavelength: 214 nm; the sustained release curve of exenatide was drawn, and the results are shown in Figure 15. The results confirmed that the exenatide glass can achieve slow release of the drug.

[0173] Example 24 Comparison of Release Rates of Aspartic Acid Glass and Crystalline

[0174] Specifically, the initial mass of aspartic acid glass was 15 ± 1 mg, the slow-release solvent was 10 mL PBS (0.01 M, pH = 6.8), and the stirring rate was 100 r min -1 The dissolved aspartic acid was detected by high performance liquid chromatography (HPLC) conditions: liquid elution conditions: mobile phase: methanol and sodium acetate solution (volume ratio of 43:57), flow rate: 0.5 mL min -1 Column temperature: 40°C, detection wavelength: 267nm; plot the sustained-release curve of glassy aspartic acid. As a control, an equal mass of amino acid crystal dosage form was placed in the above sustained-release solution and incubated with stirring. The concentration of aspartic acid in the sustained-release solution was measured. Figure 16 shows the release curves of the aspartic acid glass and crystals prepared in Example 5, demonstrating that the glassy drug can enhance the dissolution rate of the amino acid.

[0175] Example 25 In vivo efficacy evaluation of aspartic acid glass

[0176] Specifically, the ordered spontaneous type II diabetes model mice (male, 8 weeks old) were divided into three groups, with 6 mice in each group. The mice in the experimental group were gavaged with glassy aspartate drug every day, with a dose of 4 mg kg -1 The control group of mice was gavage-fed with an equal mass of normal saline solution for 30 days. Blood was collected daily from the mice's tails, and their fasting blood glucose levels were measured using a blood glucose meter. A curve was plotted with time on the horizontal axis and the fasting blood glucose levels of the experimental mice on the vertical axis. Figure 17 shows the blood glucose regulation curve of the aspartic acid glass prepared in Example 5 on mice with spontaneous type 2 diabetes, demonstrating effective blood glucose control in mice.

[0177] Example 26 High Performance Liquid Chromatography (HPLC) Method for Detecting Exenatide Glass Stability

[0178] High performance liquid chromatography (HPLC) conditions: Liquid elution conditions: mobile phase A-water (0.1% TFA), mobile phase B-acetonitrile (0.1% TFA); elution gradient: mobile phase B 20%-60%, 0-16 min; flow rate 1 mL min -1 , detection wavelength: 214nm;

[0179] The pancreatic exenatide glass prepared in Example 10 was placed in a storage chamber maintained at 40°C and 96% relative humidity (RH) together with an equivalent amount of exenatide solution. After storage in the chamber for 1, 3, 7, and 14 days, the exenatide content was measured. At the designated time points, the array was removed from the chamber and treated with 0.1 mol L -1Acetic acid (1 mL) was used to dissolve the exenatide glass to obtain an exenatide solution. The exenatide content of the resulting washing solution was analyzed using a high performance liquid chromatography (HPLC) method. The stability of the exenatide in the prepared glass was compared and analyzed by measuring the exenatide solution under the same storage conditions as a reference. The peak area of ​​exenatide in the selected samples was measured and divided by the peak area of ​​exenatide initially measured to determine the percentage of undegraded exenatide remaining in the glass or solution at each time point. The results are listed in Table 2.

[0180] The above results show that in the 14-day accelerated stability experiment, the stability of exenatide glass is significantly better than that of the solution group, indicating that the prepared exenatide glass can effectively protect the activity of bioactive molecules and facilitate long-term storage.

[0181] Example 27 Pharmacodynamic evaluation of thymopentin glass in rats.

[0182] Experimental Methods: 28 SPF male SD rats, weighing 180-220 g, were used. They had not taken any other medications prior to the experiment. Thymopentin powder was dissolved in physiological saline to prepare a thymopentin solution, which served as a reference preparation. The test preparation was the thymopentin glass dosage form prepared in Example 8. The 28 SD rats were randomly divided into four groups, designated Groups 1 to 4, with seven rats in each group, for in vivo pharmacodynamic studies.

[0183] Before the experiment began, an immunosuppressive model was established. The immunosuppressant cyclophosphamide powder was purchased from Jiangsu Hengrui Medicine Co., Ltd. and prepared with normal saline to a concentration of 1 mg L -1 Except for group 1, the other three groups of rats were given 35 mg kg -1 d -1 The first group was used as the blank control group and injected with 35mL / kg of normal saline intraperitoneally. -1 .

[0184] After the model was successfully established after three consecutive days of injection, the pharmacodynamic evaluation was performed. The rats in group 1 served as the blank control group and the rats in group 2 served as the negative control group. Both groups received subcutaneous intravenous injection of 1 mL kg saline. -1 The third group of rats served as the positive control group and were subcutaneously injected with thymopentin solution at a dose of 100 μg kg -1 The rats in group 4 were subcutaneously implanted with the thymopentin glass drug prepared in Example 8 at a dose of 100 μg kg -1The drug was administered for 7 consecutive days. The rats in the three groups were then killed by cervical dislocation. The thymus and spleen of each rat were collected and weighed, and the organ index was calculated. The formula for calculating the organ index is as follows:

[0185] Where W0 is the mass of the thymus or spleen, and W is the weight of the rat. As shown in Figure 18, the spleen and thymus coefficients in Group 2 of the negative control group were lower than those in Group 1 of the blank control group, confirming the successful establishment of the immunosuppressive model. The spleen and thymus coefficients in Groups 3 and 4 of the treatment group were higher than those in the negative control group of the model group, demonstrating statistically significant improvements in the organ coefficients of immunosuppressed rats, confirming that the glass thymus pentaphylline is more effective than the solution formulation.

[0186] Conducting activity evaluation of 28-tuftsin glass

[0187] Experimental model and methods: Experimental autoimmune encephalomyelitis (EAE) mice were constructed. Specifically, in the EAE group, 200 μg MOG35-55 was dissolved in 200 μl PBS buffer and then mixed with 200 μl complete Freund's adjuvant (CFA) to form an emulsion (the final concentration of inactivated tuberculin bacilli was 5 mg ml -1 ), while the normal control group was treated with a direct mixture of 200 μl PBS and 200 μl CFA. 200 μg of the emulsion was subcutaneously injected at two points on the back of the mouse. 500 ng of pertussis toxin was injected intraperitoneally at 0 and 48 hours after immunization. On the first day after the EAE model was established, glass Tuftsin was subcutaneously embedded in the back of the mouse at a dose of 100 μg kg -1 , administered for 7 consecutive days to prepare the solid glass Tuftsin intervention group.

[0188] Neurological function scores of experimental mice in each group were scored every day after immunization and observed for 30 consecutive days.

[0189] Neurological function was scored according to the following criteria: 0 = no symptoms; 1 = tail hypotonia (complete weakness, inability to curl the tail tip) or hindlimb weakness (unsteady gait); 2 = tail and hindlimb weakness; 3 = hindlimb paralysis (some unilateral or bilateral hindlimb movement); 4 = complete hindlimb paralysis (complete inability to move the hindlimbs or forelimbs dragging the hindlimbs); 5 = death. The results are shown in Figure 19, demonstrating that the solid glass Tuftsin intervention group effectively restored the nervous system of mice.

[0190] Implementing 29 biomolecular glass processing into microneedle devices

[0191] Biomolecular glass can be fabricated into microneedle devices using a PDMS mold casting method. Preparation method: Preheat the arginine glass prepared in Example 1 to 80°C and then pour it into a PDMS microneedle female mold, filling both the tip and base of the microneedle mold. Rapidly decompress the mold for 10 minutes to degas. Cool the mold to room temperature. After the microneedle body solidifies, demold the microneedle glass to obtain arginine-soluble glass microneedles.

[0192] The obtained arginine-soluble glass microneedles are shown in FIG20 . The left picture is a top view of the microneedle, and the right picture is a side view of the microneedle. It can be seen that the prepared microneedle body is neat and complete.

[0193] Implementation of 30 biomolecular glass to prepare rigid biodegradable coatings

[0194] The vancomycin viscous liquid prepared in Example 14 was applied to the surface of a PEI flexible electrode and heated further to obtain a flexible electrode with a vancomycin glass coating. This electrode imparts implant rigidity to the flexible electrode during in vivo implantation. After the electrode is implanted in a mouse, the vancomycin glass coating gradually degrades upon exposure to physiological fluids, restoring the electrode to a flexible state and maintaining its good conformal deformation. The vancomycin glass coating can act as a sustained-release anti-inflammatory drug, mitigating implant damage.

[0195] Implemented 31 biomolecular glass processing into optical waveguide devices

[0196] The phenylalanine glass prepared in Example 2 was melt-stretched to produce corresponding glass fibers. Optical waveguide testing was performed using 532nm and 616nm lasers, respectively. The results are shown in Figure 21. Figure 21 (left) shows a photograph of the 532nm laser transmission, while Figure 21 (right) shows a photograph of the 616nm laser transmission. It can be seen that the laser can be transmitted along the glass fibers, indicating that the biomolecular glass can be used in optical waveguide devices.

[0197] Implementing 32 biomolecular glass processing into transient electronic devices

[0198] The arginine glass prepared in Example 1 was 3D-printed to form a simulated circuit (Figure 22a). The simulated circuit had a machining accuracy of 0.2 mm. In a water environment (trigger condition) (Figure 22b), the biomolecular glass rapidly dissolved, rapidly destroying the simulated circuit pattern until it disappeared (Figure 22c). This property demonstrates that the biomolecular glass can be used as an interconnect material, for example, in the fabrication of transient electronic devices.

[0199] Implementation of 33 biomolecular glass processing into transient electronic devices

[0200] The arginine glass prepared in Example 1 was cast to form a transparent substrate film. Vacuum evaporation was then performed using a stainless steel mask to form interdigital electrodes (Figure 23a). The interdigital electrodes had a machining accuracy of 0.1 mm. In a water environment (trigger condition), the biomolecule glass substrate film rapidly dissolved within 10 seconds (Figure 23b). The interdigital electrodes disappeared instantly, and the biomolecule substrate film also completely dissolved (Figure 23c). This property demonstrates that the biomolecule glass can be used as a substrate material and encapsulation material for the fabrication of transient electronic devices.

Claims

1. A biomolecular glass, characterized in that: The biomolecule glass is obtained from a solution of a biomolecule raw material by volatilizing a solvent, wherein the solution of the biomolecule raw material comprises a biomolecule raw material, a regulator and a solvent; the biomolecule raw material comprises natural amino acids or peptides or amino acid derivatives or peptide derivatives or a mixture of the above two or more.

2. The biomolecular glass according to claim 1, wherein the natural amino acid is one or a combination of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine, pyrrolysine or salts thereof; The peptide is a molecule or a salt thereof formed by condensation of n natural amino acids through peptide bonds, wherein n≥2; preferably, 2≤n≤10; The amino acid derivatives are amino acid derivatives with protective groups on the above-mentioned natural amino acids, and the protective groups are selected from one or more combinations of Trt, Boc, Fmoc, Cbz / Z, Allyl, C2-C18 acyl, benzoyl, naphthoyl, OFm, Otbu, OBzl, OAll, OMe and OEt; The peptide derivative refers to a peptide in which at least one natural amino acid is replaced by the amino acid derivative.

3. The biomolecular glass according to claim 1, wherein the regulator is selected from nucleotides, nucleotide polymers, RNA, DNA and others, or a mixture of two or more of the above; the nucleotide is selected from one or more combinations of adenosine-5′-monophosphate (AMP), nicotinamide mononucleotide (NMN), guanosine-5′-monophosphate (GMP), uridine-5′-monophosphate (UMP), cytidine-5′-monophosphate (CMP) and adenosine-3′-monophosphate (3-AMP); the other regulator is selected from one or more combinations of D / L-tartaric acid, hydrochloric acid, sulfuric acid, phosphoric acid, lactic acid, polylactic acid, hyaluronic acid, alginic acid, lactobionic acid, citric acid, tartaric acid, oxalic acid, D / L-malic acid, maleic acid, hibiscus acid, acamprosate, quinic acid, adipic acid, fumaric acid, caproic acid, heptanoic acid, octanoic acid, valeric acid, butyric acid, propionic acid and acetic acid. The biomolecular glass according to claim 1 , wherein the solvent is water or a salt solution thereof.

5. The biomolecular glass according to any one of claims 1 to 4, characterized in that: The biomolecular glass is an amorphous body in a glassy state, and its light transmittance at a thickness of 1 mm and a wavelength of 500 nm is 40-99%, preferably 80-99%; its hardness is greater than 10 MPa, preferably greater than 50 MPa.

6. The biomolecular glass according to any one of claims 1 to 5, characterized in that: The mass percentage of the biomolecule raw material in the glass is 50-100%, preferably 85-100%; the mass percentage of the regulator in the glass is 0-50%, preferably 0-15%.

7. The biomolecular glass according to any one of claims 1 to 6, characterized in that: The biomolecular glass is prepared by a preparation method comprising the following steps: (1) Weighing biomolecule raw materials, mixing and grinding them evenly; (2) dissolving the raw material powder of step (1) in a solvent to obtain a biomolecule solution; (3) adding a regulator to the biomolecule solution of step (2), and adjusting the final pH value of the solution by controlling the amount of the regulator; (4) placing the aqueous solution of step (3) in a container, and volatilizing the solvent by adjusting the solution temperature, and / or applying pressure, and / or vacuum, to prepare biomolecular glass. 8 . The biomolecular glass according to claim 7 , wherein the final pH is 1 to 8; preferably, the final pH is 4 to 7.

9. Implantable or non-implantable medical materials and / or devices, filling and scaffold materials, electronic sensor materials and / or devices, transient electronic materials and / or devices, which are made of the biomolecular glass described in any one of claims 1 to 8.

10. Application of the biomolecular glass according to any one of claims 1 to 9 in medical care, health monitoring, security encryption, information transmission and storage.

Citation Information

Patent Citations

  • Controllable degraded multielement amino acid copolymer-organic calcium / phosphor salt filling type composite bone implantation substance and preparation method thereof

    CN104307048A

  • Composite material of bioglass / amino acid polymer and application thereof

    CN105536054A

  • Application of biologically absorbable polyphosphate and amino acid copolymer material

    CN106823010A

  • Controllably degradable bone implantation composite material and preparation method thereof

    CN111437440A

  • Glass based on amino acids as well as preparation method and application thereof

    CN113754556A